- Home
- PSHG vs ANTX Comparison
PSHG vs ANTX Comparison
Compare PSHG & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSHG | ANTX |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8M | 31.2M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | PSHG | ANTX |
|---|---|---|
| Price | $2.13 | $1.13 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | ★ 128.4K | 58.5K |
| Earning Date | 02-19-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.34 | N/A |
| Revenue | ★ $79,691,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $44.97 | N/A |
| P/E Ratio | $1.59 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.31 | $1.01 |
| 52 Week High | $2.58 | $1.55 |
Technical Indicators
Market Signals| Indicator | PSHG | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.01 | 50.17 |
| Support Level | $2.01 | $1.03 |
| Resistance Level | $2.35 | $1.15 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 28.55 | 50.00 |
Price Performance
Historical ComparisonAbout PSHG Performance Shipping Inc.
Performance Shipping Inc is a provider of shipping transportation services through its ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying containerized cargo along various shipping routes. It owns and operates six Aframax tanker vessels.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.